Nixon tried and failed.. but what about now? Are we ready to win a war against cancer within the next decade? Jerold Mande, an associate director for health policy at the Yale Cancer Center, says we can. We have the tools to do it. We just need the will.
A New War on Cancer
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Nixon tried and failed.. but what about now? Are we ready to win a war against cancer within the next decade? Jerold Mande, an associate director for health policy at the Yale Cancer Center, says we can. We have the tools to do it. We just need the will.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Cardiology
Phase 3 study results of plozasiran in patients with FCS
<p>Phase 3 study results of plozasiran in patients with FCS</p>
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
<p>FCS and SHTG: Are We Meeting the Need?</p>
CME/CE
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
0.50 credits
<p>IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement</p>
CME/CE
Personalizing Care Within the RCC Treatment Paradigm
1.00 credits
<p>Personalizing Care Within the RCC Treatment Paradigm</p>
Clinician's Roundtable
AI and Hair Loss: Measuring Progress with Data-Driven Insights
<p>AI and Hair Loss: Measuring Progress with Data-Driven Insights</p>
Clinician's Roundtable
Challenges in AI-Driven Dermatology: Understanding Current Limitations
<p>Challenges in AI-Driven Dermatology: Understanding Current Limitations</p>
Cardiology
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
<p>Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial </p>
ACC Action Center
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
<p>Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?